A study on adverse events of botulinum toxin type A in real‐world applications: A FAERS database analysis
British Journal of Clinical Pharmacology · 2025
DOI: 10.1002/bcp.70141 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Weizhen He und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Provincial Hospital of Fuzhou University, Fu Zhou, Fujian, China. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Adverse Drug Reaction Reporting Systems, Neuromuscular Agents. Die Arbeit nennt 28 Literaturangaben. Gefördert von: Guidance in Medical and Health Program of Xiamen, China.
Themen: Patientensicherheit
Abstract (Originalsprache)
Aims
Botulinum toxin type A (BoNT‐A) is widely used for its efficacy in treating a variety of neuromuscular disorders. However, data on its safety and adverse events (AEs) in real‐world settings remain limited. The Food and Drug Administration Adverse Event Reporting System (FAERS) database provides an invaluable resource for evaluating the safety of BoNT‐A.
Methods
We used four methods to evaluate the disproportionality of AEs associated with BoNT‐A: the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the multi‐item gamma Poisson shrinker (MGPS).
Results
Among the 17 307 196 case reports in the FAERS database, there were 69 644 reports where BoNT‐A was listed as the “primary suspect” for AEs. BoNT‐A‐related AEs affected 27 system organ classes (SOCs). Based on the four algorithms, 290 significant disproportionalities at the Preferred Term (PT) level were retained. Unexpected AEs, such as skin wrinkles, hyperacusis, Guillain‐Barré syndrome, mediastinitis and infective aneurysm, were identified, which are not mentioned in the product insert.
Conclusion
This study provides an overview of AEs in the real‐world use of BoNT‐A, revealing its broad safety profile. Although the majority of AEs were mild to moderate, there is a need to remain vigilant for serious AEs and to monitor them in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Provincial Hospital of Fuzhou University, Fu Zhou, Fujian, China.
- Department of Neurosurgery, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China.
- Xiamen Medical Quality Control Center for Neurosurgery, Xiamen, Fujian, China.
- Department of Otolaryngology, Xiang'an Hospital of Xiamen University, Xiamen, Fujian, China.
- Department of Ophthalmology, Xiang'an Hospital of Xiamen University, Xiamen, Fujian, China.
ORCID-Profile: Weizhen He
Förderung
- Guidance in Medical and Health Program of Xiamen, China
Zitieren
APA
He, W., Guo, J., Xu, Y., Huang, X., & Chen, K. (2025). A study on adverse events of botulinum toxin type A in real‐world applications: A FAERS database analysis. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70141
Vancouver
He W, Guo J, Xu Y, Huang X, Chen K. A study on adverse events of botulinum toxin type A in real‐world applications: A FAERS database analysis. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70141
BibTeX
@article{He2025,
author = {He, Weizhen and Guo, Jian and Xu, Yingqian and Huang, Xiaoling and Chen, Kaiqin},
title = {A study on adverse events of botulinum toxin type A in real‐world applications: A FAERS database analysis},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/bcp.70141}
}
EUVIMED